Maravai Lifesciences Holdings (MRVI) Change in Receivables (2020 - 2026)

Maravai Lifesciences Holdings' Change in Receivables history runs 7 years deep, the most recent figure standing at $7.9 million for Q1 2026.

• On a quarterly basis, Change in Receivables rose 177.89% year-over-year to $7.9 million in Q1 2026; TTM through Mar 2026 was $5.3 million, a 179.23% increase from a year earlier, with the FY2025 full-year figure at -$12.8 million, up 10.75% from the prior year.
• Change in Receivables climbed to $7.9 million in Q1 2026 per MRVI's latest filing, from $3.0 million in the prior quarter.
• Across five years, Change in Receivables topped out at $25.8 million in Q4 2022 and bottomed at -$82.4 million in Q1 2023.
• The 5-year median for Change in Receivables is -$1.9 million (2024), against an average of -$4.8 million.
• Across the five-year window, Change in Receivables tumbled 6674.78% in 2023 and soared 177.89% in 2026, its largest moves.
• Year by year, Change in Receivables stood at $25.8 million in 2022, then slumped by 65.92% to $8.8 million in 2023, then jumped by 30.11% to $11.4 million in 2024, then tumbled by 74.09% to $3.0 million in 2025, then surged by 167.27% to $7.9 million in 2026.
• Per Business Quant, the three latest MRVI Change in Receivables figures stand at $7.9 million (Q1 2026), $3.0 million (Q4 2025), and -$5.1 million (Q3 2025).